ERBB2 and breast cancer: Much previous evidence supports the role of HER2 in RT resistance, and HER2+/CD44+/CD24−/low cells, Fak activation in vitro and in vivo, and STAT3-survivin signaling may be associated with RT resistance in HER2+ breast cancer patients (26–28).